CVS Stock Soars: Is This Healthcare Giant's Rally Just Starting?

CVS Health stock, long overlooked by investors, has surged roughly 24% over the past month. The catalyst was a surprisingly strong first-quarter earnings report that handily beat Wall Street's expectations.

The company reported revenue of $100.4 billion, a 6.2% year-over-year increase, and earnings per share (EPS) of $2.30, which soared 62% compared to the same period last year. Both figures significantly outpaced analyst forecasts.

Encouraged by the results, management raised its full-year guidance. It now expects adjusted EPS between $7.30 and $7.50 and projects cash flow from operations of at least $9.5 billion.

The rally was further fueled by a notable turnaround in its previously struggling health insurance segment, Aetna, where profitability improved as medical costs were better controlled.

This matters because CVS appears to be fixing its biggest problem: weak margins. The improvement in Aetna's medical benefit ratio is a critical sign that its integrated business model is starting to deliver promised efficiencies.

CVS's unique position as a combined pharmacy, insurer, and benefits manager creates a defensive moat. This vertical integration allows it to capture value at multiple points in the healthcare chain, a strategy pure-play rivals like Walgreens or Humana can't easily copy.

With a dividend yield of 2.8%—more than double the S&P 500 average—supported by strong cash flow, the stock offers income alongside growth potential. Analyst upgrades and an average price target near $102 suggest confidence in further upside.

However, a major concern remains: the company's massive debt load of $86.4 billion. While CVS is actively reducing it, this leverage limits financial flexibility for buybacks or aggressive expansion.